Radiofrequency Ablation May Be Beneficial for RCC

Share this content:
Radiofrequency Ablation May Be Beneficial for RCC
Radiofrequency Ablation May Be Beneficial for RCC

STOCKHOLM—Radiofrequency ablation (RFA) can provide durable oncologic control in patients with biopsy-proven renal cell carcinoma (RCC), according to study findings presented at the European Association of Urology 29th annual congress.

In a study of 90 patients with a median age of 69.5 years who underwent RFA for biopsy-proven small RCC tumors, investigators observed local tumor recurrence in only 1 patient after a median follow-up of 55 months. Five patients (5.5%) died of cancer-related causes and 7 (7.7%) died from non-cancerous causes. Tumor size was not associated with a higher risk of death.

RELATED: Renal Cell Carcinoma Resource Center

The study, led by Steven Joniau, MD, of University Hospitals Leuven in Belgium, showed that the only variables associated with decreased overall survival were age at RFA and preoperative chronic kidney disease (CKD) stage.

Dr. Joniau's group concluded in their poster presentation that RFA “may be a valid treatment approach, especially in poor surgical candidates. Elderly patients or patients with renal function impairment … at diagnosis have a considerable risk of dying within 5 years of non-cancer related causes and may be spared treatment.”

In the study cohort, 45 patients had tumors smaller than 30 mm and 45 had tumors 30 mm or larger. The median tumor size was 29.5 mm. In addition, 55 patients had no preoperative CKD. Ten had CKD stage 2, 13 had CKD stage 3, and 2 had CKD stage 4 preoperatively. CKD status was not available for 10 patients.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs